The
global Subdermal Contraceptive Implants Market size is
expected to reach USD 969.2 million by 2026, according to a new report by Grand
View Research, Inc., registering a 3.2% CAGR over the forecast period.
Introduction of several modern contraceptives in the market, growing awareness
about various birth control methods, and high per capita income are some of the
key factors driving the market for subdermal implants for birth control.
According
to the Guttmacher Institute, in 2014, approximately 20 million women needed
publicly funded contraceptive services. According to CDC, in 2017, nearly 46.9
million women in the U.S. were using at least one method of contraception.
Subdermal implant is a long-term birth control option for women. Subdermal
implants for contraception are in the form of polymer capsules or rods placed
under the skin. The progestational hormone is released at a slow and stable
rate, providing effective contraception for 1-5 years.
Publicly
funded family planning services help women avoid or plan pregnancies. In 2012,
the South Carolina Department of Health and Human Services (SCDHHS) revised the
cost associated with Medicaid payment policy for immediate postpartum insertion
of Long-Acting Reversible Contraception (LARC). Under this new reimbursement
policy, providers are allowed to bill for the insertion procedure and the cost
of an IUD or an implant, in addition to the Diagnosis Related Group (DRG) by
using J-codes with a family planning modifier.
Implants
are the most widely used contraceptive methods by women in sub-Saharan Africa
owing to public-private partnerships between manufacturers, donors,
governments, and international agencies, which helps lower commodity cost and
increase product availability. Contraceptive usage has increased in South
Africa, Malawi, and Rwanda. According to PLOS.org, in Malawi, the use of the
Long-acting Reversible Contraception (LARC) method reached 10.21% in urban
areas in 2016 and 9.66% in rural areas. In 2012, an initiative called Family
Planning 2020 (FP2020) was launched to give 120 million women access to modern
contraceptive methods by 2020.
Request
a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/subdermal-contraceptive-implants-market
Further key findings from the report suggest:
- North
America held the maximum share in the market for subdermal implants for
contraception in 2018. This can be attributed to growing number of
unwanted pregnancies, increased government initiatives in favor of
contraception, and rising unmet needs
- Strong
economic growth in countries such as China, India, and Singapore,
increasing awareness about contraceptives and STIs, and rising disposable
income are expected to boost the Asia Pacific market in the coming years
- Rapid
population growth is a major concern in sub-Saharan African countries; the
region’s population growth is projected to account for more than half of
the global population growth by 2050. This could have a positive impact on
the uptake of subdermal implants for birth control
- Some of the
key subdermal contraceptive implants market players are Shanghai Dahua
Pharmaceutical Co., Ltd.; Merck & Co., Inc.; and Bayer AG. In February
2018, Shanghai Dahua Pharmaceutical Co., Ltd. and DKT International
entered into an agreement to market Levoplant at a reduced price of USD
6.90 per unit in 69 countries.
About Us:
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, the company offers market intelligence
studies ensuring relevant and fact-based research across a range of industries
including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment